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Abstract
Our laboratory has previously identified an important intragenic region in the human immunodeficiency virus type 1 (HIV-1)
genome, whose complete functional unit is composed of the 5103 fragment, the DNaseI-hypersensitive site HS7 and the
5105 fragment. These fragments (5103 and 5105) both exhibit a phorbol 12-myristate 13-acetate (PMA)-inducible enhancer
activity on the herpes simplex virus thymidine kinase promoter. Here, we characterized the three previously identified AP-1
binding sites of fragment 5103 by showing the PMA-inducible in vitro binding and in vivo recruitment of c-Fos, JunB and
JunD to this fragment located at the end of the pol gene. Functional analyses demonstrated that the intragenic AP-1
binding sites are fully responsible for the PMA-dependent enhancer activity of fragment 5103. Moreover, infection of T-
lymphoid Jurkat and promonocytic U937 cells with wild-type and mutant viruses demonstrated that mutations of the
intragenic AP-1 sites individually or in combination altered HIV-1 replication. Importantly, mutations of the three intragenic
AP-1 sites led to a decreased in vivo recruitment of RNA polymerase II to the viral promoter, strongly supporting that the
deleterious effect of these mutations on viral replication occurs, at least partly, at the transcriptional level. Single-round
infections of monocyte-derived macrophages confirmed the importance of intragenic AP-1 sites for HIV-1 infectivity.
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Introduction
Human immunodeficiency virus type 1 (HIV-1) gene expression
is regulated at the transcriptional level by cis-acting elements
located in the viral 59 long terminal repeat (59LTR) and leader
region, by trans-acting factors including the viral transactivating
Tat protein and cellular transcription factors that are either
constitutively expressed in most cells (such as Sp1 and Oct-1) or
inducible in T cells and macrophages (such as NF-kB and NFAT),
and by the chromatin organization of the HIV-1 provirus [1]. In
addition to the 59LTR enhancer, our laboratory has previously
identified a phorbol 12-myristate 13-acetate (PMA)-inducible
intragenic enhancer located in the coding region of HIV-1 [2].
It is composed of two functional domains termed fragment 5103
(located at the end of the pol gene and encompassing nucleotides
(nt) 4079 to 4342, where nt +1 is the beginning of U3 in the
59LTR) and fragment 5105 (encompassing nt 4781 to 6026, which
correspond to vif and the first coding exon of tat). These fragments
both exhibit a PMA-inducible enhancer activity on the herpes
simplex virus (HSV) thymidine kinase (TK) promoter in the
human epithelial HeLa cell line, but no significant activity in T-
lymphoid and monocyte-macrophage cell lines [2].
Furthermore, our laboratory has studied the chromatin
organization of HIV-1 proviruses integrated in several latently-
infected cell line models of T-lymhoid (ACH2 and 8E5) or
monocytic (U1) origin [3,4,5]. Besides the anticipated presence of
DNaseI-hypersensitive sites in the two LTRs, a single major
hypersensitive site (named HS7) was identified in the part of the pol
gene coding for the integrase (centred around nt 4490–4766) [3,5],
thereby indicating a potential transcriptional regulatory role of this
region. This constitutive hypersensitive site was observed only in a
cell line of monocytic origin (U1) and not in two cell lines of
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e19084
lymphoid origin (8E5 and ACH2) [3], suggesting a certain cellular
specificity associated to this site. Interestingly, the HS7 is
positioned between the previously identified 5103 and 5105
fragments. Several ubiquitous and cell-specific transcription factors
have been shown to be recruited in the HS7 region (including Oct-
1, Sp1/Sp3 and PU.1) [5,6] and to be important for viral
infectivity [6]. Altogether, these results demonstrate the impor-
tance of the intragenic cis-regulatory region, whose complete
functional unit is composed of the 5103 fragment, the hypersen-
sitive site HS7 and the 5105 fragment (see Figure 1).
Given that the enhancer activity of the HIV-1 intragenic region
had been demonstrated to be inducible by phorbol-esters [2], our
laboratory has previously examined this region for the presence of
binding sites for PMA-inducible transcription factors (such as NF-
kB, AP-1, AP-2 and AP-4). In this context, we have identified
three AP-1 binding sites in fragment 5103 by in silico analyses
based on nucleotide sequence homologies to the consensus DNA
recognition motif of AP-1 transcription factors [59-(A/T)T(G/
T)(A/C)(G/C)TCA(G/C/A)-39] [7]. Short oligonucleotides con-
taining the two first AP-1 sites or the third AP-1 site were
demonstrated to bind in vitro affinity-purified AP-1/c-Jun or AP-1
present in PMA-induced HeLa nuclear extracts [7]. In addition to
the two AP-1 binding sites previously described in the 59LTR
negative regulatory element (NRE) of different HIV-1 neurotropic
strains [8], three AP-1 sites have been characterized by our
laboratory downstream of the transcription start site in a large
nucleosome-free region termed HS4 (nt 465-720), which functions
as an enhancer towards HIV-1 59LTR transcriptional activity [9].
The AP-1 transcription factors, originally identified by their
binding to the enhancer element of the simian virus 40 (SV40)
promoter [10], function as homo- or heterodimers composed of
members of the jun, fos and atf multigene families [11]. Dimerizing
via their basic leucine zipper domain and thereby members of the
wider B-ZIP family, AP-1 transcription factors bind DNA at
palindromic sequences, also known as 12-O-Tetradecanoylphor-
bol-13-acetate (TPA or PMA) Responsive Elements (TREs) [12],
to regulate both the constitutive and the inducible transcription of
a wide variety of cellular and viral genes [11,13]. The negative or
positive role of AP-1 in the transcriptional activity of a specific
target gene depends on cell type, dimer-composition, abundance
of each dimer partner, translational regulation mechanisms [14],
post-translational modifications [including phosphorylation
[15,16] and sumoylation [17,18]] and AP-1 interactions with
transcriptional (co)factors such as SWI/SNF [19]. Particularly,
phosphorylation of AP-1 by the protein kinase ERK1/2
(Extracellular Regulated Kinase 1/2) promotes AP-1 interaction
with NF-kB in the HIV-1 59LTR, leading to transcriptional
activation [20,21]. AP-1 activity is induced by a wide range of
stimuli such as growth factors, cytokines, bacterial and viral
infections and numerous physical and chemical stresses. AP-1
plays important roles in various cellular processes including
cellular proliferation and differentiation, apoptosis, signalling,
stress responses, cell migration and tumorigenesis [11].
In this report, we have characterized biochemically each of the
three intragenic AP-1 binding sites. We have examined the
functional role of these AP-1 binding sites (individually or in
combination) for the PMA-dependent enhancer activity of the
5103 fragment, in the presence or absence of the viral
transactivating Tat protein. Importantly, we have investigated
the biological significance of the intragenic AP-1 binding sites for
HIV-1 replication both in cell lines and in primary macrophages
(MDMs).
Materials and Methods
Cell lines and cell culture
The T-lymphoid cell lines Jurkat [22] and SupT1 [23] were
obtained from the AIDS Research and Reference Reagent
Programme (National Institute of Allergy and Infectious Diseases
[NIAID], National Institutes of Health [NIH]). The monocytic cell
line U937 was obtained from the American Type Culture
Collection (Manassas, VA). The U937, Jurkat and SupT1 cell
lines were maintained in RPMI 1640-Glutamax I medium
(Invitrogen) supplemented with 10% fetal bovine serum (FBS),
50 mg/ml streptomycin and 50 units/ml penicillin. The adherent
cell lines HeLa (a human epithelial cell line derived from a cervical
carcinoma and transformed by human papilloma virus type 18),
TZM-bl (an HeLa-derivative cell line that expresses high levels of
HIV-1 receptor CD4 and both co-receptors CXCR4 and CCR5,
Figure 1. Schematic representation of the intragenic cis-regulatory region of HIV-1. The complete functional unit of the intragenic cis-
regulatory region encompasses nt 4079 to nt 6026 and is composed of the 5103 fragment, the hypersensitive site HS7 and the 5105 fragment. The
three AP-1 binding sites of fragment 5103 are indicated as well as the previously characterized binding sites of the HS7 region (site B which binds
Oct-1 and a T cell specific complex termed B3 or the monocyte/macrophage lineage-specific complex PU.1, the GC-box which binds Sp1 and Sp3, site
C which binds Oct-1 and a T-cell specific complex termed C3 and site D which binds unidentified complexes [6]).
doi:10.1371/journal.pone.0019084.g001
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and contains b-galactosidase and luciferase reporter genes under
the control of the HIV-1 LTR) and 293T (a human embryonic
kidney cell line) were cultured in Dulbecco’s modified Eagle’s-
Glutamax I medium (Invitrogen) supplemented with 5% FBS,
50 mg/ml streptomycin and 50 units/ml penicillin (containing
1 mM sodium pyruvate for the 293T cells). All cells were grown at
37uC in an atmosphere of 5% CO2.
MDMs isolation and culture
Peripheral blood mononuclear cells (PBMCs) were isolated from
buffy coats of healthy seronegative donors (Centre de Transfusion
Sanguine Ile-de-France Rungis, Paris, France) by density centri-
fugation on a Ficoll-Hypaque gradient (PAA). Monocytes were
isolated from PBMCs by plastic adherence and differentiated into
macrophages by culturing for 7 to 11 days in MDM medium
(RPMI 1640 medium supplemented with 200 mM L-glutamine,
100 units/ml penicillin, 100 mg/ml streptomycin, 10 mM HEPES,
10 mM sodium pyruvate, 50 mM b-mercaptoethanol, 1% mini-
mum essential medium vitamins, and 1% nonessential amino
acids) containing 15% of human AB serum (PAA) in hydrophobic
Teflon dishes (LumoxTM, D Dutscher). Prior to infection
experiments, MDMs were harvested, washed and resuspended in
MDM medium containing 10% fetal calf serum.
Plasmid constructs and generation of mutated reporter
constructs by site-directed mutagenesis of the pol gene
AP-1 binding sites
The A-Fos dominant negative construct was kindly provided by
Dr. Charles Vinson (NCI, National Cancer Institute, Bethesda,
MD 20892, USA) [24]. The expression vectors coding either for
the one-exon form of Tat (72 amino acids, named pTat72) or the
two-exon form of Tat (101 amino acids, named pTat101) were
previously described [25]. The pTK reporter construct contains
the luciferase gene under the control of the HSV TK minimal
promoter and was generated by subcloning the XmaCI-XhoI
fragment from the pGL2-TK (see [26]) into the XmaCI-XhoI-
restricted pGL3-basic vector (Promega). The pLTR containing the
HIV-1 59LTR upstream of the luciferase gene in the context of the
pGL3-basic vector was previously described [6].
Mutations of the AP-1 binding sites were introduced in the 5103
fragment following the QuikChange site-directed mutagenesis kit
manufacturer’s protocol (Stratagene), using 50 ng of the pCV10
construct as a substrate (pBluescript II SK vector which contains
an ApaI-EcoRI fragment corresponding to nt 2011-5743 of the
HIV-1NL4.3 genome and previously described [6]) and the
following pairs of mutated oligonucleotide primers (mutations
are highlighted in boldface and the AP-1 motifs are underlined on
the coding strand): CV1364-CV1365 (site AP-1#1mut: FW: 59-
GCACAACCAGATAAGTCAGAATCAGAGT TAGTCAGT-
CAA-39; RV: 59-TTGACTGACTAACTCTGATTCTGACT-
TATCTGGT TGTGC-39), CV1366-CV1367 (site AP-1#2mut,
FW: 59-AAGAGTGAATCAGAGTT GGTTAGTCAAATAA-
TAGAG-39; RV: 59-CTCTATTATTTGACTAACCAACTCT-
GAT TCACTCTT-39), CV728-CV729 (site AP-1#3mut, FW:
59-CAAGTAGATAAATTGG TTAGTGCTGGAATC-39; RV:
59-GATTCCAGCACTAACCAATTTATCT ACTTG-39) and
CV1151-CV1152 (site AP-1#1+2mut, FW: 59-ACAACCAGA-
TAAGTCAGAATCA GAGTTGGTTAGTCAAATAATAG-39;
RV:59-CTATTATTTGACTAACCAACTCTGATT CTGACT-
TATCTGGTTGT-39). Following PCR, the samples were treated
for two hours with the endonuclease DpnI, which is specific for
methylated and hemi-methylated DNA (target sequence 59-
Gm6ATC-39) and digested the parental wild-type DNA template
to select for mutation-containing plasmids. Mutated clones were
fully resequenced between ApaI and EcoRI restriction sites after
identification (Genomex). The four mutated resulting pCV10-
derivative plasmids were designated pCV1208 (AP-1#1mut),
pCV1209 (AP-1#2mut), pCV1202 (AP-1#3mut) and pCV1210
(AP-1#1+2mut), respectively. A pCV10-derivative construct
containing a combination of the three AP-1 mutations described
above was also generated and designated pCV887 (AP-1#totmut).
The ApaI-EcoRI mutagenized fragments from pCV887,
pCV1202, pCV1208, pCV1209 and pCV1210 were introduced
into the unique ApaI-EcoRI sites of the two-LTRs-containing
infectious HIV-1 molecular clone pNL4.3 (reagent no. 114,
received from the AIDS Research and Reference Reagent
Program, NIAID, NIH) to generate pCV1352 (termed pHIV-1-
AP-1#totmut), pCV1393 (pHIV-1-AP-1#3mut), pCV1394
(pHIV-1-AP-1#1mut), pCV1395 (pHIV-1-AP-1#2mut) and
pCV1396 (pHIV-1-AP-1#1+2mut), respectively. As a control, a
nonmutated ApaI-EcoRI fragment was purified from pCV10 and
cloned in an identical manner into the unique ApaI-EcoRI sites of
the pNL4.3, construction now referred to as pHIV-1.
The pol gene fragment (nt 4079-4342) corresponding to the
5103 fragment from the infectious proviral molecular clone pNL4-
3 was amplified by PCR. XmaCI sites were introduced into the
PCR primers, and the XmaCI-restricted PCR fragment was
cloned into the unique XmaCI site of the pTK, placing the
amplified fragment upstream of the TK-luciferase transcriptional
unit in the sense or antisense orientation, thereby generating the
pTK-5103s-wt or the pTK-5103as-wt, respectively. The 59
oligonucleotide primer encompassed the coding strand sequence
from nt 4079 to 4099 and contained an added XmaCI restriction
site (underlined) at the 59 end (CV596: 59-TCCCCCGGGATC-
C[4079]AGATAAGAGTGAA TCAGAGTT-39). The 39 oligo-
nucleotide primer encompassed the complementary sequence
from nt 4328 to 4342 and contained an added XmaCI site
(underlined) at the 59 end (CV598: 59-TCCCCCGGGATCC-
CAGCTG [4342]GCTACTATTTCTTTT-39). Fragments con-
taining the 5103 region mutated in the three AP-1 binding sites
individually or in combination were PCR amplified from the
pCV887, pCV1202, pCV1208, pCV1209 and pCV1210 plasmids
(see above). The 59 and 39 oligonucleotide primers were as
described above except for the pCV887, pCV1208 and pCV1210
plasmids, which contain mutations in the AP-1#1 site. In these
latter cases, the 59 oligonucleotide primer was as follows: 59-
TCCCCCGGGATCC[4079]AGATAAGTCAGAATCAGAGT-
T-39 (the added XmaCI restriction site is underlined and
mutations in the AP1#1 site are highlighted in boldface). The
different amplified fragments were digested with XmaCI and then
ligated into the unique XmaCI site of pTK in the antisense
orientation, thereby generating the pTK-5103as-AP-1#totmut,
the pTK-5103as-AP-1#3mut, the pTK-5103as-AP-1#1mut, the
pTK-5103as-AP-1#2mut and the pTK-5103as-AP-1#1+2mut
constructs, respectively.
Electrophoretic Mobility Shift Assays (EMSAs)
Nuclear extracts were prepared from cells using a rapid protocol
described by Osborn et al. [27]. All buffers contained the following
protease inhibitors: antipain (10 mg/ml), aprotinin (2 mg/ml),
chymostatin (10 mg/ml), leupeptin (1 mg/ml) and pepstatin
(1 mg/ml). Protein concentrations were determined according to
the Bradford methodology [28], with bovine serum albumin (BSA)
as a standard. The DNA sequences of the coding strand of the
wild-type and mutated versions of the AP-1#1, AP-1#2 and AP-
1#3 probes used in this study are listed in Figures 2A and 3A,
respectively. The various lengths of these oligonucleotides, which
Intragenic AP-1 Sites Role in HIV-1 Replication
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Figure 2. AP-1 transcription factors specifically bind in vitro to each of the three intragenic AP-1 sites of fragment 5103. (A) The
nucleotide sequence of the wild-type AP-1#1, AP-1#2 and AP-1#3 site oligonucleotides used as probes in our EMSAs are shown properly aligned
with the AP-1 consensus sequence. The position of the AP-1 binding site is indicated by an arrow on each coding strand and mismatches in the AP-1
sites with respect to the AP-1 consensus sequence are designated by asterisks. The conservation of the intragenic AP-1 sites was assessed by
comparing their sequences at the nucleotide level based on the full spectrum of HIV and SIV sequences compiled in the HIV compendium database
(hiv-web.lanl.gov). Sequence logos that represent the frequency of the nucleotide present at each position in the intragenic AP-1 binding sites were
generated based on these sequence analyses for each intragenic AP-1 site. (B) The AP-1#1, AP-1#2 and AP-1#3 oligonucleotide probes were
incubated with nuclear extracts (10 mg) from mock-treated (lane 1) or PMA-treated (lanes 2 to 6) HeLa cells in the absence of competitor (lanes 1 and
2) or in the presence of a molar excess (5 fold) of a competitor corresponding to the homologous AP-1 site (lane 3), to the heterologous Sp1
consensus (lane 4; nucleotide sequence of the coding strand: 59-ATTCGATCGGGGCGGGGCGAGC-39), to the AP-1 consensus (lane 5; nucleotide
sequence of the coding strand: 59-CGCTTGATGACTCAGCCGGAA-39) or to the mutated AP-1 consensus (lane 6; nucleotide sequence of the coding
strand: 59-CGCTTGATGACTTGGCCGGAA-39, where mutations compared to the consensus are indicated in bold). The figure shows the specific
retarded bands of interest, which are indicated by arrows. The terms C1, C2 and C3 refer to complexes 1, 2 and 3. (C) Nuclear extracts from PMA-
treated HeLa cells (10 mg) were incubated, before the addition of the AP-1 probe, either with a purified rabbit IgG as a negative control (lane 1), or with
an antibody directed against AP-1 family members including c-Fos (lane 2), FosB (lane 3), Fra-1 (lane 4), Fra-2 (lane 5), c-Jun (lane 6), JunB (lane 7) and
JunD (lane 8), or with an antibody directed against other members of the B-ZIP family such as CREB (lane 9), CREM (lane 10), ATF-1 (lane 11), ATF-2 (lane
12), C/EBPa (lane 13), C/EBPb (lane 14) and C/EBPd (lane 15), or with an antibody directed against Ets-1 (lane 16). The figure shows the specific retarded
bands of interest indicated by arrows. Supershifted complexes are indicated by asterisks. (D) Ten mg of nuclear extracts from PMA-treated HeLa cells
were incubated with an antibody directed against c-Fos (lane 18), an antibody directed against JunB (lane 19) or a combination of both antibodies (lane
20). A purified rabbit IgG was used as a negative control (lane 17). The AP-1#1, AP-1#2 or AP-1#3 oligonucleotide probe was then added to the
mixture. The figure shows the specific retarded bands of interest indicated by arrows. The supershifted complexes are indicated by asterisks.
doi:10.1371/journal.pone.0019084.g002
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results from design constraints, may account for the different
numbers of complexes observed with the different probes. EMSAs
were performed as described previously [26]. Briefly, nuclear
extracts (10 mg of protein) were first incubated for 10 min in the
absence of probe and specific competitor DNA in a 16 ml reaction
mixture containing 10 mg of DNase-free BSA (Amersham
Biosciences), from 0.5 to 2 mg of poly(dI-dC) (Amersham
Biosciences) as non-specific competitor DNA, 50 mM ZnCl2,
0.25 mM DTT, 20 mM HEPES (pH 7.3), 60 mM KCl, 1 mM
MgCl2, 0.1 mM EDTA and 10% (v/v) glycerol. 30,000 cpm of
probe (80 - 100 fmol) were then added to the mixture with or
without a molar excess of an unlabeled specific DNA competitor,
and the mixture incubated 20 min at room temperature. Samples
were subjected to electrophoresis on 6% polyacrylamide gels at
120 V for 2-3 h in 1x TGE buffer [25 mM Tris-acetate (pH 8.3),
190 mM glycine and 1 mM EDTA]. Gels were dried and
autoradiographed for 24-48 h at -80uC. For supershift assays,
antibodies against c-Fos (sc-52X), FosB (sc-48X), Fra-1 (sc-605X),
Fra-2 (sc-171X), c-Jun (sc-44X), JunB (sc-73X), JunD (sc-74X),
CREB (sc-240X), CREM (sc-440X), ATF-1 (sc-243X), ATF-2 (sc-
242X), C/EBPa (sc-9314X), C/EBPb (sc-150X), C/EBPd (sc-
151X) and Ets-1 (sc-350X) or a purified rabbit immunoglobulin
(IgG; sc-2027) were added to the reaction mixture and incubated
for 30 min on ice before the addition of the radiolabelled probe.
Transient transfection and luciferase reporter assays
HeLa cells were transiently transfected using JetPEITM
(POLYplus) according to the manufacturer’s protocol. Briefly,
one day before transfection, cells were seeded at a density of
86103 cells/well in 96-well plates. For each well, 200 ng of DNA
were diluted into 25 ml of 150 mM NaCl. The transfection reagent
JetPEITM (0.45 ml/well) was diluted into 150 mM NaCl (25 ml/
well). An aliquot of 25 ml of this JetPEITM/NaCl solution was
added to the 25 ml DNA solution, and the JetPEITM/NaCl/DNA
mixture incubated for 15 min at room temperature before being
added dropwise to each well. All transfection mixtures contained
the pRL-TK (in which a cDNA encoding the Renilla luciferase is
under the control of the HSV TK promoter region) as an internal
control for transfection efficiency. At 24 hours after transfection,
cells were mock-treated or treated with PMA (20 nM) (Sigma). At
24 post-treatment, transfected cells were lysed and assayed for
luciferase activity. Firefly luciferase activities derived from the HSV
TK promoter were normalized with respect to the Renilla
luciferase activities by using the DualGlo-luciferase reporter assay
system (Promega), and to protein concentrations using the
Bradford quantification method [28]. Statistical analyses of the
data were performed and p-values are indicated in the figure
legends.
Chromatin immunoprecipitation assays
The chromatin immunoprecipitation (ChIP) assays were
performed as previously described by Flanagin et al. [29,30] with
minor modifications. Briefly, cells in exponential growth phase
were cross-linked for 10 min at room temperature with 1%
formaldehyde (whose action was then neutralized with TRIS-
Glycin 12.5 mM), washed twice with phosphate-buffered saline
(PBS) and lysed in IP buffer (150 mM NaCl, 50 mM Tris–HCl
pH 7.5, 5 mM EDTA, 0.5% NP-40, 1% Triton X-100)
containing protease inhibitors (Roche). To detect chromosomal
flanking regions, pellets were sonicated (Bioruptor sonicator) to
obtain DNA fragments of an average size of 400 nt. Chromatin
immunoprecipitations were performed in commercially available
protein-A-coated 96 well plates (Pierce). After two washes (200 ml
PBS/well), well walls were blocked with 200 ml blocking buffer (IP
buffer completed with 5% BSA and 100 mg/ml sheared salmon
sperm DNA) for 30 min. Wells were cleared and then incubated
with antibodies (0.5 mg) in 100 ml blocking buffer/well for 60 min.
Wells were cleared and chromatin samples (80,000 cells in 100 ml
blocking buffer) were added and incubated overnight at 4uC. Wells
were then washed three times with 200 ml IP buffer and once with
200 ml TE buffer, before being incubated with 100 ml elution
buffer (25 mM Tris base, 1 mM EDTA, pH 9.8, 200 mg/ml
proteinase K) for 15 min at 55uC, followed by 30 min at 75uC.
DNA samples were stored (220uC) in the same Matrix ChIP
plates for repeated use. Antibodies directed against AP-1 family
members used in this study were described above, an antibody
Figure 3. Identification of point mutations which abolish AP-1 transcription factors’ in vitro binding to their respective binding sites
located in fragment 5103. (A) The wild-type and mutated AP-1#1, AP-1#2 and AP-1#3 oligonucleotide sequences are indicated as well as the
corresponding underlying amino acid sequence of the viral reverse transcriptase. Base pairs which were modified in the mutated versions of the AP-1
binding sites relative to the wild-type versions are indicated by asterisks. (B) The AP-1#1, AP-1#2 and AP-1#3 oligonucleotide probes were
incubated with nuclear extracts (10 mg) from mock-treated (lane 1) or PMA-treated (lanes 2 to 6) HeLa cells in the absence of competitor (lanes 1 and
2) or in the presence of increasing molar excesses (2 and 4 fold) of each respective homologous AP-1 oligonucleotide (lanes 3 and 4) or of the
corresponding mutated AP-1 oligonucleotide (lanes 5 and 6). The figure shows the specific retarded bands of interest, which are indicated by arrows.
doi:10.1371/journal.pone.0019084.g003
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directed against RNA polymerase II (sc-899) was also used, and a
purified IgG (I-1000, Vector Laboratories) was used as a control
for immunoprecipitation to test aspecific binding to the plate.
Quantitative real-time PCR (qPCR) reactions were performed
using the MesaGreen qPCR mastermix (Eurogentec) with 5 ml of
the eluted DNA product. Relative quantification using the
standard curve method was performed for each primer pair and
96-well Optical Reaction plates were read in an Applied
Biosystems AbiPrism 7300 real-time PCR instrument (Absolute
Quantification Method). Fold enrichments were calculated as
percentages of input values. Primer sequences used for quantifi-
cation in the 5103 fragment region (FW: 59- GGGAATCATT-
CAAGCACAACC-39; RV: 59- TCTTGGGCCTTATC TATT-
CCATC-39), in the nuc-1 region ([31]; FW: 59- GACTGGT-
GAGTACGCCAAA -39; RV: 59- TAATACTC GACGCTC-
TCGC -39) and in an unrelated viral region corresponding to the
vpr gene (FW: 59- GCAACAACTGCTGTTTATCCATT-39; RV:
59- TTTCTTGCTCTCCTCTGTCGAG-39) were designed us-
ing the software Primer Express 2.0 (Applied Biosystems).
Production of viral stocks
The generated wild-type and mutated full-length molecular
clones were used to produce stocks of wild-type and mutant viruses
(termed HIV-1, HIV-1-AP-1#totmut, HIV-1-AP-1#1mut, HIV-
1-AP-1#2mut, HIV-1-AP-1#3mut and HIV-1-AP-1#1+2mut).
The infectious DNAs (750 ng) were transiently transfected into 107
Jurkat cells using the DEAE-dextran procedure. At 24 h
posttransfection, cultures were co-cultivated with 107 SupT1 cells
to allow rapid and efficient recovery of progeny viruses. HIV-1
stocks were prepared from culture supernatants after filtration
through a 0.45-mm-pore-size membrane (Nalgene) and were
quantified by determining p24 antigen concentration using an
enzyme-linked immunosorbent assay (ELISA) (Innogenetics). Each
viral stock was verified by sequence analyses of HIV-1 genomic
RNA in order to confirm the presence of the originally introduced
mutations using the following procedure: viral particles from each
stock were pelleted by ultracentrifugation (at 20,0006 g for 2 h at
4uC) and digested with RNase-free DNase I (110 U/ml for 15 min
at room temperature [Invitrogen]) in the presence of RNaseOUT
(40 U/ml; Invitrogen) to remove contaminating DNA. HIV-1
genomic RNA was purified using the High Pure Viral RNA Kit
(Roche Applied Science) following the manufacturer’s protocol.
cDNA synthesis was performed by the Titan One Tube RT-PCR
Kit method (Roche Applied Science). cDNAs were then amplified
by PCR with a 59 oligonucleotide primer corresponding to nt
3882–3907 (59-GCAGCCAATAGG GAAACTAAATTAGG-39)
and a 39 oligonucleotide primer corresponding to nt 5056–5035
(59-GCCATCTGTTTTCCATAATCCC-39). PCR fragments
were subcloned into the vector pCR4 Blunt-TOPO (Zero Blunt
TOPO PCR Cloning Kit [Invitrogen]). After identification of
recombinant clones, three inserts from each construct were
sequenced (Genomex). The nucleotide sequences of all three
clones were identical and confirmed the presence of originally
introduced mutations.
Infection assays in cell lines
First, infectivity of wild-type and mutant viruses was assessed in
TZM-bl cells. In brief, exponentially growing cells were seeded at
66103 cells/200 ml in 96 well plates and were infected or not with
equal amounts of wild-type or mutant viruses (corresponding to
20 ng of p24 antigen). At 72 h post-infection, TZM-bl cells were
lysed in PBS and luciferase activity was measured (Promega).
Second, infections of Jurkat and U937 cells were performed by
incubating 0.56106 cells with 50 ng of p24 protein of wild-type or
mutant viruses (at 37uC for 2 h in 500 ml of culture medium). After
infection, cells were pelleted at 3006 g, washed three times with
1 ml of culture medium, resuspended in 1 ml of culture medium,
and grown under standard conditions. Every 2 or 3 days, aliquots
of 200 ml were removed from the infected cultures and replaced by
fresh medium. The aliquots were assayed for p24 concentration in
triplicate in order to monitor the kinetics of viral replication. In
addition, total RNA was extracted from infected cells at days 5, 10
and 15 post-infection using the RNeasy Plus Mini Kit (Qiagen)
and digested with TURBO DNase I (Ambion) to ensure the
removal of genomic DNA. First strand cDNA was synthesized
using SuperScript III Reverse Transcriptase and random primers
(Invitrogen). qPCR reactions were performed as described above
with the comparative Ct (DDCt) quantification method. The
following sets of primers were used for amplification of initiated
viral transcripts (TAR: FW: 59-GTTAGACCAGATCT-
GAGCCT-39; RV: 59-GTGGGTTCCCTAG TTAGCCA-39)
and elongated transcripts (Tat mRNAs: FW: 59- ACTCGACA-
GAGGAGAGCA AG-39; RV: 59- GAGTCTGACTGTTCT-
GATGA-39), using b-actin (FW: 59- GTCGACAACGGCT
CCGGC-39; RV: 59- GGTGTGGTGCCAGATTTTCT-39) to
normalize the results.
Production of VSV-G pseudotyped viruses and single-
round infectivity assays in MDMs
HIV-1/VSV-G (Vesicular Stomatitis Virus Glycoprotein)
pseudotypes were produced by transiently cotransfecting 293T
cells with the generated HIV-1NL4.3 wild-type or mutant full length
molecular clones and the pMD2 VSV-G expression vector.
Supernatants containing pseudotyped viral particles were collected
at 48 h post-transfection, filtered through a 0.45-mm-pore-size
membrane and stored at 280uC. Viral stocks were termed HIV-
1VSV-G, HIV-1-AP-1#1mutVSV-G, HIV-1-AP-1#2mutVSV-G,
HIV-1-AP-1#3mutVSV-G, HIV-1-AP-1#1+2mutVSV-G and HIV-
1-AP-1#totmutVSV-G. HIV-1 p24 antigen in viral stocks was
quantified using an ELISA kit (Innogenetics). Each viral stock was
verified by sequence analyses of HIV-1 genomic RNA in order to
confirm the presence of the originally introduced mutations as
described above. For single-round infections, MDMs (0.86105
cells/well in 96 well plates) were infected in triplicate with 100 ml
of HIV-1/VSV-G pseudotyped viruses (containing equivalent
concentrations of p24) using a spinoculation protocol (1 h
centrifugation at room temperature at 1,2006 g followed by 1 h
incubation at 37uC). Cells were then washed with PBS and
cultured in MDM medium. At days 3 and 6 post-infection, the
supernatant of each well was replaced by fresh medium and at day
10 post-infection, p24 concentration in the supernatants was
measured by ELISA.
Western blotting
HIV-1 lysates were prepared by ultracentrifugation of each
virus stock (500 ng of p24 at 20,0006 g for 2 h at 4uC) and the
pellets were resuspended in Laemmli buffer at a concentration of
8.3 ng of p24/ml. Lysates were heated at 95uC for 5 min,
separated by electrophoresis on a 10% polyacrylamide gel and
transferred onto a polyvinylidene difluoride membrane. The
membrane was then blocked in Tris-buffered saline (TBS)
containing 5% non-fat dry milk and incubated with a purified
human anti-HIV-1 IgG (NIH AIDS Research and Reagent
Program, reagent no. 192 donated by Dr Alfred Prince). A
horseradish peroxidase-conjugated goat anti-human IgG (Pierce)
was then used for enhanced chemiluminescence detection (Cell
Signalling). The dominant negative A-Fos mutant was detected in
nuclear extracts from transiently transfected cells using an anti-
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FLAG antibody (Sigma) followed by a second horseradish
peroxidase-conjugated anti-mouse IgG used for enhanced chemi-
luminescence detection (Cell Signalling).
Results
AP-1 transcription factors specifically interact in vitro with
each of the three AP-1 sites located in the HIV-1 5103
fragment
Our laboratory has previously identified three AP-1 binding
sites in the 5103 fragment of the HIV-1 intragenic cis-regulatory
region by in silico analyses [7]. Short oligonucleotides containing
the two first AP-1 binding sites or the third AP-1 binding site,
respectively, were previously demonstrated by our laboratory to
bind in vitro affinity-purified AP-1/c-Jun or AP-1 present in PMA-
treated HeLa nuclear extracts by EMSAs (competition experi-
ments) [7]. In order to pursue the in vitro characterization of the
intragenic AP-1 sites, we performed additional EMSAs using three
oligonucleotide probes containing each site individually (termed
AP-1#1, AP-1#2 and AP-1#3 probe, respectively, and designed
based on the nucleotide sequence of the infectious HIV-1NL4.3
isolate). The three intragenic AP-1 binding sites are very well
conserved at the nucleotide level as represented in Figure 2A by
sequence logos that symbolize the frequency of the nucleotide
present at each position in these binding sites based on sequence
analyses of the full spectrum of HIV and SIV (Simian
Immunodeficiency Virus) sequences compiled in the HIV
compendium database (hiv-web.lanl.gov). Of note, the third AP-
1 binding site sequence is slightly different in the HIV-1NL4.3 strain
compared to the other strains since it contains a guanine residue at
position 4 in the TRE sequence instead of an adenine or a cytosine
(as in the AP-1#3 site from most of other HIV-1 strains or in the
AP-1 consensus sequence), a mutation that has been shown in the
literature to impede AP-1 binding to TREs [32].
The radiolabelled probes were incubated with nuclear extracts
from mock-treated (Figure 2B, lane 1) or PMA-treated (20 nM for
one hour; lanes 2 to 6) HeLa cells in the absence (lanes 1 and 2) or
presence of different unlabelled double-stranded oligonucleotides
as competitors, corresponding either to the homologous sequence
(i.e. the same sequence as that of the radiolabelled probe; lane 3),
or to the heterologous Sp1 binding site consensus (lane 4), or to the
AP-1 binding site consensus (lane 5; named AP-1 cons), or to a
mutated version of the AP-1 binding site consensus (lane 6; named
AP-1 cons mut). As shown in Figure 2B, incubation of the AP-1#1
probe with nuclear extracts from mock-treated HeLa cells resulted
in the formation of a broad retarded complex designated AP-1#1-
C1 (Fig. 2B, top panel, lane 1). When nuclear extracts from PMA-
treated HeLa cells were used, the intensity of the AP-1#1-C1
complex increased markedly (Fig. 2B, top panel, lane 2).
Moreover, formation of the AP-1#1-C1 complex was competed
for by a molar excess of the unlabeled homologous AP-1#1
oligonucleotide (Fig. 2B, top panel, lane 3), but not by the same
molar excess of a heterologous oligonucleotide of unrelated
sequence (Fig. 2B, top panel, lane 4), thereby demonstrating the
sequence specificity of complex AP-1#1-C1 binding to the AP-
1#1 probe. Furthermore, the addition of a molar excess of an
unlabeled oligonucleotide corresponding to an AP-1 binding site
consensus (Fig. 2B, top panel, lane 5) hindered the formation of
the AP-1#1-C1 complex, whereas this complex formation was not
competed for by the same molar excess of a mutated version of the
AP-1 consensus (Fig. 2B, top panel, lane 6), thereby demonstrating
that the AP-1#1-C1 complex is specific to the AP-1 motif.
Incubation of the AP-1#2 probe with nuclear extracts from
mock-treated HeLa cells resulted in the formation of three
retarded complexes designated AP-1#2-C1 to AP-1#2-C3
(Fig. 2B, middle panel, lane 1) that were all specific to the AP-
1#2 sequence as demonstrated by competition with homologous
and heterologous oligonucleotides (Fig. 2B, middle panel, lanes 3
and 4). The slower migrating complex AP-1#2-C1 was strongly
induced following PMA-treatment of the cells (Fig. 2B, middle
panel, lane 2). A molar excess of the unlabelled AP-1 consensus
oligonucleotide (Fig. 2B, middle panel, lane 5), but not of its
mutated version (Fig. 2B, middle panel, lane 6), specifically
inhibited the formation of this PMA-inducible AP-1#2-C1
complex, whereas no differences in the binding of the AP-1#2-
C2 and AP-1#2-C3 complexes were observed, thereby showing
that the AP-1#2-C1 complex is specific to the AP-1 motif.
Finally, three retarded complexes were observed using the AP-
1#3 probe, including a PMA -inducible complex termed AP-1#3-
C3 (Fig. 2B, bottom panel, lanes 1 and 2). These three retarded
complexes were shown to be specific to the AP-1#3 sequence by
competition experiments with homologous and heterologous
competitors (see Fig. 2B, bottom panel, lanes 3 and 4, respectively).
Moreover, the AP-1#3-C3 complex was demonstrated to be
specific to the AP-1 motif since its formation was completely
inhibited by a molar excess of the AP-1 consensus oligonucleotide
(Fig. 2B, bottom panel, lane 5), but only slightly affected by the
same molar excess of the mutated AP-1 consensus oligonucleotide
(lane 6). However, even with a low concentration of poly(dI-dC), a
non-specific DNA competitor, the AP-1#3-C3 complex was
difficult to observe. These low affinity binding properties are in
good correlation with the presence of a guanine residue at position
4 in the TRE of the AP-1#3 site in the HIV-1NL4-3 isolate, which
markedly decreases AP-1 binding efficiency [32].
In order to directly identify the factors present in the PMA-
inducible AP-1#1-C1, AP-1#2-C1 and AP-1#3-C3 complexes,
we performed supershift assays using antibodies directed against
individual members of the AP-1 family and against members of
the related C/EBP family of B-ZIP transcription factors
(Figures 2C and 2D). Radiolabelled AP-1 probes incubated with
PMA-treated HeLa nuclear extracts and either a purified rabbit
IgG (Fig. 2C, lane 1) as a negative control or an antibody directed
against c-Fos, FosB, Fra-1, Fra-2, c-Jun, JunB, JunD, CREB,
CREM, ATF-1, ATF-2, C/EBPa, C/EBPb, C/EBPd or Ets-1
(Fig. 2C, lanes 2 to 16).
The addition of an antibody directed against JunD or against c-
Fos interfered with the formation of complex AP-1#1-C1 and led
to the appearance of a supershifted complex of decreased mobility
(Fig. 2C, top panel, lane 8; Fig. 2C, top panel, lane 2 and Fig. 2D,
top panel, lane 18, respectively). The addition of an anti-JunB
antibody also hindered the formation of complex AP-1#1-C1,
generating two supershifted complexes (Fig. 2C, top panel, lane 7;
Fig. 2D, top panel, lane 19). The AP-1#1-C1 complex intensity
decreased less markedly following the addition of an antibody
directed against JunD than following the addition of an anti-cFos
or an anti-JunB antibody (Fig. 2C, top panel; compare lane 8 with
lanes 2 and 7), suggesting a smaller contribution of JunD in the
composition of the AP-1#1-C1 complex. Interestingly, when both
anti-cFos and anti-JunB antibodies were included in the same
binding reaction, the AP-1#1-C1 complex entirely disappeared
(Fig. 2D, top panel, lane 20), confirming that c-Fos and JunB
corresponded to the predominant AP-1 species which bound to
the AP-1#1 site. In contrast, the binding pattern observed
following incubation of the AP-1#1 probe with PMA-treated
HeLa nuclear extracts was weakly affected or not affected at all by
the addition of antibodies directed either against the other AP-1
family members (Fig. 2C, top panel, lanes 3 to 6), or against other
members of the B-ZIP family (Fig. 2C, top panel; lanes 9 to 15) or
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against the Ets-1 transcription factor (Fig. 2C, top panel; lane 16),
supporting the notion that the PMA-inducible retarded complex
AP-1#1-C1 did not contain these other proteins. As a control, all
the antibodies that did not supershift AP-1 complexes in this study
were demonstrated to be functional in EMSAs with other
radiolabelled probes (data not shown). Moreover, no retarded
band was affected neither by the addition of a purified rabbit IgG
used as a negative control (Fig. 2C, top panel, lane 1; Fig. 2D, top
panel, lane 17) nor by the addition of antibodies to the probe alone
(data not shown), indicating the specificity of the protein-antibody
interactions. Similar results were obtained for the AP-1#2-C1 and
AP-1#3-C3 complexes (Fig. 2C and 2D, middle and bottom
panels, respectively).
Taken together, our results demonstrate that each of the three
intragenic AP-1 sites located in the pol gene 5103 fragment bind in
vitro the c-Fos, JunB and to a lesser extent JunD transcription
factors of the AP-1 family.
Identification of mutations abolishing AP-1 binding to
the AP-1 sites of fragment 5103
To further characterize biochemically and functionally the AP-1
sites located in fragment 5103, we designed point mutations aimed
at abolishing AP-1 binding to their respective binding site, without
altering the underlying amino acid sequence of the viral reverse
transcriptase.
We substituted the adenine residue at position 4086, the
guanine residue at position 4087 and the thymine residue at
position 4088 from the AP-1#1 probe by a thymine, a cytosine
and an adenine residue, respectively (see Figure 3A, top panel) to
generate its mutated version designated AP-1#1mut. We
evaluated the impact of this 3-bp mutation on AP-1 binding by
competition EMSAs with the AP-1#1 oligonucleotide as a probe
and nuclear extracts from mock-treated and PMA-treated HeLa
cells (Fig. 3B, top panel, lane 1 and lanes 2 to 6, respectively). As
expected, the PMA-inducible AP-1#1-C1 specific complex was
inhibited by competition with increasing molar excesses of the
homologous AP-1#1 oligonucleotide (Fig. 3B, top panel, lanes 3
to 4). However, this complex was not competed for by the same
molar excesses of the AP-1#1mut oligonucleotide (Fig. 3B, top
panel, lanes 5 to 6), thereby demonstrating that selected mutations
abolish AP-1 binding to the AP-1#1 site. Moreover, we confirmed
the lack of AP-1 binding to the mutated AP-1#1mut probe and
the absence of new complexes compared to the pattern observed
with the wild-type probe (data not shown).
The same approach was followed to identify mutations
hindering AP-1 binding to the AP-1#2 and AP-1#3 sites of
fragment 5103 and to demonstrate their ability to abolish in vitro
AP-1 binding to their respective sites (Figures 3A and 3B,
respectively). Moreover, we confirmed the lack of AP-1 binding
to the mutated AP-1#2mut and AP-1#3mut probes (data not
shown).
In conclusion, we identified selected mutations which abrogate
AP-1 binding to their respective binding site without altering the
underlying amino acid sequence of the HIV-1 reverse transcrip-
tase.
The intragenic AP-1 binding sites are fully responsible for
the PMA-dependent enhancer activity of fragment 5103
In order to address the potential functional role of the three
intragenic AP-1 binding sites in the context of the whole 5103
fragment, we inserted this 264-bp fragment into the pTK reporter
construct immediately upstream of the TK-luciferase transcrip-
tional unit in the sense or antisense orientation, thereby generating
the pTK-5103s-wt and the pTK-5103as-wt, respectively. The
constructs pTK, pTK-5103s-wt and pTK-5103as-wt were tran-
siently cotransfected into the human epithelial HeLa cell line with
the pRL-TK (in which a cDNA encoding the Renilla luciferase is
under the control of the HSV TK promoter region) used as an
internal control for transfection efficiency. Twenty-four hours
post-transfection, cells were mock-treated or treated with PMA.
Twenty-four hours post-treatment, cells were lysed and assayed for
luciferase activity.
As shown in Figure 4, the plasmids pTK-5103s-wt and pTK-
5103as-wt presented no significant activity compared to that of
the control vector pTK in basal conditions. However, in the
presence of PMA, transfection of plasmid pTK-5103s-wt or of
plasmid pTK-5103as-wt resulted in a 1.93-fold ( = 2.68/1.39)
or in a 5.11-fold ( = 7.41/1.45) induction of the measured
luciferase activity, respectively. By normalizing the results in
agreement with the control vector pTK activity (1.28-fold)
following PMA-treatment of the cells, the observed increases in
luciferase activity of these constructs represent a 1.51-fold
( = 1.93/1.28) or a 4.00-fold ( = 5.11/1.28) activation, respec-
tively. These results indicate that the PMA-dependent enhancer
activity of fragment 5103 shows a strong preference for the
antisense orientation of this fragment with respect to the
luciferase transcriptional unit.
We next investigated the relative contribution of each AP-1
binding site (AP-1#1, AP-1#2 and AP-1#3) to the PMA-
dependent enhancer activity of fragment 5103. To this end, the
mutations identified above as able to abolish AP-1 in vitro binding
to their respective recognition sequence were introduced individ-
ually or in combination in the context of the pTK-5103as-wt by
site-directed mutagenesis. The mutated plasmids were designated
pTK-5103as-mut1, pTK-5103as-mut2, pTK-5103as-mut3, pTK-
5103as-mut1+2 and pTK-5103as- totmut, and were tested for
their PMA-responsiveness by transient transfection experiments in
HeLa cells (Figure 4).
In basal conditions, the mutated constructs exhibited luciferase
activities similar to that obtained with the control vector pTK,
such as what we observed with the wild-type construct pTK-
5103as-wt. Remarkably, following PMA-treatment of the cells, the
plasmid pTK-5103as-totmut (where the three intragenic AP-1 sites
have been mutated simultaneously) exhibited a luciferase activity
similar to that obtained with the control vector pTK under the
same conditions (Fig. 4), thereby indicating that the PMA-
dependent enhancer activity of fragment 5103 required the
integrity of the AP-1 motifs located in this fragment. In addition,
transfection of plasmids pTK-5103as-mut1, pTK-5103as-mut2
and pTK-5103as-mut3 resulted in a 2.63-fold ( = 3.78/1.43), 3.11-
fold and 4.40-fold PMA induction, respectively, compared to the
5.11-fold PMA induction obtained with the wild-type construct
pTK-5103as-wt (Fig. 4). This corresponds to a 49% and 39% loss
in the PMA-dependent enhancer activity of fragment 5103 when
the AP-1#1 or the AP-1#2 site were mutated, respectively,
whereas mutation in the AP-1#3 binding site resulted in a less
pronounced loss of this activity (14% loss). Of note, the plasmid
pTK-5103as-mut1+2 exhibited a PMA-responsiveness analogous
to that obtained with the pTK-5103as-totmut (1.69-fold),
suggesting that the two first AP-1 binding sites played a major
role in the PMA-dependent enhancer activity of fragment 5103.
In conclusion, these results demonstrate that the PMA-
dependent enhancer activity of fragment 5103 displays a strong
preference for the antisense orientation of this fragment with
respect to the transcriptional unit. Moreover, the loss of AP-1
binding to fragment 5103 significantly altered its PMA-dependent
enhancer activity.
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The PMA-dependent enhancer activity of fragment 5103
is impaired by ectopically expressed dominant-negative
A-Fos mutant
To further confirm the crucial role played by AP-1 transcription
factors in the PMA-dependent enhancer activity of fragment 5103,
we evaluated the effects of overexpression of a dominant negative
A-Fos mutant on this activity in transient transfection experiments.
The dominant negative A-Fos mutant contains an acidic
amphipathic protein sequence appended onto the N-terminus of
the Fos leucine zipper, replacing the normal basic region critical
for DNA binding [24]. This acidic extension and the Jun basic
region form a heterodimeric coiled-coil structure that stabilizes the
complex and prevents the basic region of Jun from binding to
DNA, thereby titrating the functionally active AP-1 heterodimer
concentration in the cell without altering the function of other B-
ZIP proteins [24,33]. We transiently cotransfected the control
vector pTK, the pTK-5103as-wt or the pTK-5103as-totmut
construct with increasing amounts of the expression vector
encoding the A-Fos mutant (pCG-AFos). Twenty-four hours
post-transfection, HeLa cells were mock-treated or treated with
PMA. Twenty-four hours post-induction, cell lysates were assayed
for luciferase activity (Figure 5A).
In agreement with the results presented in Figure 4, in the
absence of A-Fos, transfection of the plasmid pTK-5103as-wt
caused a 4.30-fold ( = 4.85/1.13) increase in luciferase activity
following PMA-treatment of the cells (Figure 5A), whereas
mutations present in pTK-5103as-totmut impeded the PMA-
dependent enhancer activity of the 5103 fragment (Fig. 5A).
Moreover, ectopic expression of A-Fos inhibited the PMA-
dependent enhancer activity of fragment 5103 in a dose-
dependent manner, while it did not affect the transcriptional
activity of the control vector pTK (Fig. 5A). These results
confirmed the important functional role of AP-1 transcription
factors in the PMA-dependent enhancer activity of the 5103
fragment. Furthermore, as ectopic expression of A-Fos did not
significantly affect the luciferase activity of the pTK-5103as-totmut
construct neither in mock-treated nor in PMA-treated HeLa cells
(Fig. 5A), we assumed that inhibition of the enhancer activity of
fragment 5103 by A-Fos required intact intragenic AP-1 binding
sites. Using the N-terminal FLAG epitope present on the
dominant negative A-Fos mutant, we verified by western blot
experiments that A-Fos was effectively expressed in a dose-
dependent manner and that its production was not affected by
PMA-treatment of the cells (see Figure 5B).
Altogether, these results demonstrate that AP-1-dimerizing
proteins are the transcription factors fully responsible for the
PMA-dependent enhancer activity of fragment 5103 through
interaction with the intragenic AP-1 binding sites.
The binding and functional properties of the AP-1 sites
located in fragment 5103 are independent of HIV-1 Tat
protein expression
HIV-1 transcription is boosted by the viral transactivating
protein Tat, which binds to the cis-acting RNA TAR (Transacti-
vation Response element) element located at the 59end of all
nascent viral transcripts in order to promote processive elongation
Figure 4. The intragenic AP-1 binding sites are fully responsible for the PMA-dependent enhancer activity of fragment 5103. HeLa
cells were transiently transfected with 200 ng of the following constructs: the control vector pTK, the pTK-5103s-wt, pTK-5103as-wt, pTK-5103as-
totmut, pTK-5103as-mut1, pTK-5103as-mut2, pTK-5103as-mut3 or pTK-5103as-mut1+2 reporter construct. All transfection mixtures additionally
contained the pRL-TK (1 ng), in which a cDNA encoding the Renilla luciferase gene is under the control of the HSV TK promoter. At 24 h post-
transfection, cells were mock-treated (-) or treated with PMA (+) (20 nM). Luciferase activities (Firefly and Renilla) were measured in cell lysates 48 h
after transfection. Results are expressed as LuciferaseFirefly/[Proteins]*LuciferaseRenilla and presented as histograms indicating the luciferase activities of
each construct relative to that of the control vector pTK, which was assigned an arbitrary value of 1 in absence of PMA. Means and standard errors of
the means from three independent transfection experiments each performed in triplicate are indicated. The PMA induction of each TK construct is
written in the upper part of the Figure (in fold). * indicates p,0.05 compared with the wild-type construct.
doi:10.1371/journal.pone.0019084.g004
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[34]. In addition to viral transactivation, Tat has been shown to
modulate the activity of several transcription factors either via
direct interaction (such as previously reported for Oct-2 [35] and
NFAT [36]) or via indirect mechanisms (including Tat-mediated
alteration of Sp1 [37], NF-kB [38] and AP-1 [36] transcriptional
activities). This prompted us to test whether Tat could alter the
functional role of the intragenic AP-1 sites.
To determine whether Tat expression affects the in vitro binding
of AP-1 factors to each individual intragenic AP-1 binding site, we
performed EMSAs with nuclear extracts from mock-treated or
PMA-treated HeLa cells expressing the one-exon form of Tat
(pTat72, see the Materials and Methods section), or the two-exon
form of Tat (pTat101) (Figure 6A). Both forms of the Tat protein
were studied because Tat101 is expressed both early and late in
the virus life cycle, while Tat72 is only expressed in the late phase
[39]. We observed no significant differences when we compared
the retarded complexes in absence of Tat versus in presence of Tat
(Figure 6A, compare lane 1 to lanes 3 and 5; lane 2 to lanes 4 and
6), neither in basal nor in PMA-induced conditions. Tat expression
in these nuclear extracts was verified by ELISA (data not shown).
These results show that Tat expression does not modulate the in
vitro binding of AP-1 to fragment 5103.
We next evaluated the potential impact of Tat expression on the
PMA-dependent enhancer activity of fragment 5103. Therefore, we
transiently cotransfected HeLa cells with the control vector pTK, the
pTK-5103as-wt or the pTK-5103as-totmut constructs and with an
expression vector encoding the Tat protein (pTat72, pTat101 or the
corresponding empty vector pREP9). Twenty-four hours post-trans-
fection, cells were mock-treated or treated with PMA. Twenty-four
hours post-induction, cellswere lysed andassayed for luciferase activity.
As shown in Figure 6B, the PMA-dependent enhancer activity
of fragment 5103 observed in the absence of Tat (a 6.11-fold
increase in luciferase activity following PMA-treatment of the cells
with the pTK-5103as-wt construct compared to the activity of the
pTK) was not affected neither by Tat72 expression nor by Tat101
expression (Fig. 6B; increasing concentrations of the Tat
expression vectors were used but only the highest dose is shown).
Control experiments confirmed that Tat was expressed and was
functional in terms of transactivation of the HIV-1 promoter in
our experimental conditions (data not shown).
In conclusion, these results indicate that the in vitro binding of
AP-1 factors to the three intragenic AP-1 sites and the functional
role of these sites in the PMA-dependent enhancer activity of
fragment 5103 are independent of Tat protein expression.
Figure 5. Overexpression of the dominant negative A-Fos mutant impairs the PMA-dependent enhancer activity of fragment 5103.
(A) HeLa cells were transiently cotransfected with 100 ng of the pTK, pTK-5103as-wt or pTK-5103as-totmut reporter construct and with increasing
amounts (0, 50 or 100 ng) of the dominant negative construct pCG-AFos. To maintain the same amount of transfected DNA and to avoid squelching
artifacts, the different quantities of A-Fos expression vector cotransfected were complemented to 100 ng of DNA by using the empty vector pCG.
Cells were additionally cotransfected with 1 ng of pRL-TK. Twenty-four hours post-transfection, cells were mock-treated (-) or treated with PMA (+).
Luciferase activities (Firefly and Renilla) were measured in cell lysates 48 h after transfection. Results are expressed as LuciferaseFirefly/LuciferaseRenilla
and presented as histograms indicating the relative luciferase activity of each construct with respect to the activity of the same reporter construct in
the absence of both PMA and A-Fos, which was assigned an arbitrary value of 1. Means and standard errors of the means from three independent
transfection experiments each performed in triplicate are indicated, with p,0.01 compared with the empty vector pTK indicated by an asterisk. (B)
A-Fos mutant expression is efficient and not affected by PMA-treatment of the cells. HeLa cells were transiently transfected with
increasing amounts (0, 2 or 4 mg) of the dominant negative construct pCG-AFos. To maintain the same amount of transfected DNA, the different
quantities of A-Fos expression vector transfected were complemented to 4 mg of DNA by using the empty vector pCG. Twenty-four hours post-
transfection, cells were mock-treated (mock) or treated with PMA (PMA) for one hour. Nuclear extracts were then prepared and analysed by western
blot with an antibody directed against the N-terminal FLAG epitope of the A-Fos mutant.
doi:10.1371/journal.pone.0019084.g005
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Figure 6. Binding and functional properties of intragenic AP-1 sites are independent of Tat protein expression. (A) HeLa cells were
transiently transfected with the expression vector pTat72 encoding the one-exon form of Tat (72 amino acids named Tat72), the expression vector
pTat101 encoding the two-exon form of Tat (101 amino acids or Tat101), or with the corresponding empty vector pREP9 used as a control. Twenty-
four hours post-transfection, cells were mock-treated (-) or treated with PMA (+) for one hour. Nuclear extracts from these transiently transfected cells
were prepared and used in EMSA experiments. The AP-1#1, AP-1#2 and AP-1#3 probes incubated with 10 mg of nuclear extracts from HeLa cells
(lanes 1 and 2), HeLa cells expressing Tat72 (lanes 3 and 4) or HeLa cells expressing Tat101 (lanes 5 and 6), which were mock-treated (lanes 1, 3 and 5)
or treated with PMA (lanes 2, 4 and 6). Retarded bands of interest are shown and indicated by arrows. (B) HeLa cells were transiently cotransfected
with 100 ng of the pTK, pTK-5103as-wt or pTK-5103as-totmut reporter construct and with 200 ng of an expression vector encoding either the one-
exon form of Tat (pTat72) or the two-exon form of Tat (pTat101) or of the corresponding empty vector pREP9. All transfection mixtures contained
1 ng of pRL-TK as a control of transfection efficiency. Twenty-four hours post-transfection, cells were mock-treated (-) or treated with PMA (+).
Luciferase activities (Firefly and Renilla) were measured in cell lysates 48 h post-transfection. Results are expressed as LuciferaseFirefly/
[Proteins]*LuciferaseRenilla and presented as histograms indicating the relative luciferase activities with respect to the activity of the control vector
pTK in the absence of PMA, which was assigned an arbitrary value of 1. Means and standard errors of the means of one representative experiment
from three independent transfection experiments each performed in triplicate are indicated. * indicates p,0.01 compared to the empty vector pTK.
doi:10.1371/journal.pone.0019084.g006
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Mutations in the intragenic AP-1 binding sites impair
c-Fos, JunB and JunD in vivo recruitment to the 5103
fragment and lead to a decreased recruitment of RNA
polymerase II to the viral promoter
In order to determine whether endogenous AP-1 transcription
factors are recruited in vivo to the HIV-1 5103 fragment, we
conducted chromatin immunoprecipitation (ChIP) experiments.
HeLa cells were transiently transfected with the wild-type plasmid
pHIV-1 (HIV-1 full-length molecular clone pNL4-3) or with its
mutated counterpart pHIV-1-AP-1#totmut (mutated in the three
intragenic AP-1 sites simultaneously). Twenty-four hours post-
transfection, cells were mock-treated or treated with PMA.
Twenty-four hours post-induction, chromatin was prepared from
these cells and immunoprecipitated with specific antibodies
directed against c-Fos, JunB, JunD, Fra-1, RNA polymerase II
(RNAPII) or with a purified IgG antibody as a control. Three
different primer pairs were designed in the 5103 fragment region
of interest, in the nuc-1 region where AP-1 binding sites had been
previously reported [8,9] and in the vpr gene, where neither the
literature nor our in silico analyses have revealed the presence of
potential AP-1 binding sites (data not shown).
As shown in Figure 7A (central panels), we observed the in vivo
recruitment of c-Fos, JunB and JunD, but not of Fra-1, to the 5103
fragment region. This recruitment increased following PMA-
treatment of the cells (compare lanes 1 and 3). These results are in
good agreement with our in vitro binding studies (see above
Figure 2B). Importantly, AP-1 recruitment to the 5103 fragment
region was significantly affected by mutations introduced in the
three intragenic AP-1 binding sites of the pHIV-1#totmut
construct, both in absence (Fig. 7A; compare lanes 1 and 2) and
in presence (compare lanes 3 and 4) of PMA. Interestingly, c-Fos,
JunB and JunD (but not Fra-1) were shown to be recruited to the
nuc-1 region (Fig. 7A, left panels), where they had been previously
demonstrated to bind (or not to bind concerning Fra-1) in vitro to
the AP-1 binding sites identified in the 59LTR [40]. As a control,
no binding of AP-1 family members was observed in the HIV-1 vpr
gene region (see Fig. 7A, right panels).
Moreover, the in vivo recruitment of RNA polymerase II to the
59LTR region increased following PMA treatment of the cells
(Figure 7B; left panel). Remarkably, the combined mutation of the
three intragenic AP-1 binding sites decreased by , two fold the
PMA-mediated RNAPII in vivo recruitment to the viral promoter
(Fig. 7B, left panel), thereby supporting the notion that the 5103
fragment AP-1 binding sites are important for HIV-1 transcrip-
tional activity.
Altogether, these results indicate that c-Fos, JunB and JunD (but
not Fra-1) are recruited in vivo to the 5103 fragment region in a
PMA-inducible manner in the context of our transient transfection
experiments. They also confirm that the designed mutations affect
c-Fos, JunB and JunD in vivo recruitment to the 5103 fragment
region without altering AP-1 recruitment to the nuc-1 region.
Importantly, mutations of the three intragenic AP-1 sites decrease
RNAPII in vivo recruitment to the viral promoter, supporting the
notion that these sites are important for HIV-1 transcriptional
activity.
The intragenic AP-1 binding sites are important for viral
replication
We next studied the biological significance of the 5103 fragment
AP-1 binding sites for HIV-1 replication. Stocks of wild-type and
mutant HIV-1 infectious viruses were produced as described in the
Materials and Methods section and used in infection assays. In
order to check that the potential effects of introduced mutations on
HIV-1 replication do not result from a serious defect in HIV-1
protein content or in HIV-1 RNA genome packaging of the virus
stocks used to perform infectivity studies, lysates and viral RNA
from equal amounts of p24 from the wild-type and mutant virus
stocks were respectively analysed by western blotting with a
purified human anti-HIV-1 IgG antibody and by RT-qPCR to
quantify the amount of viral genomic RNA in each virus stock
(Figures 8A and 8B, respectively). Similar amounts of each HIV-1
detected proteins, including the reverse transcriptase which is
partially encoded by fragment 5103, and of viral genomic RNA
were observed in all samples, supporting the notion that all virus
stocks used in the infection studies were structurally similar at both
the protein and RNA levels.
In order to evaluate the importance of the intragenic AP-1 sites
for viral expression, we infected TZM-bl cells with the wild-type
(HIV-1) and mutant (HIV-1-AP-1totmut; HIV-1-AP-1#1mut,
HIV-1-AP-1#2mut, HIV-1-AP-1#3mut and HIV-1-AP-1#1
+2mut) viral stocks (Figure 8C). TZM-bl cells, that contain the
luciferase gene under the control of the HIV-1 LTR, are easily
infected by HIV-1 since they express the receptor CD4 and both
co-receptors CXCR4 and CCR5. Once integrated into the
cellular genome, the virus begins expressing the viral Tat
protein, which then activates luciferase expression by trans-
activating the LTR transcriptional activity. Thus, luciferase
expression in those cells is a reliable reporter for viral expression.
As shown in Figure 8C, mutations in the intragenic AP-1 binding
sites affected luciferase expression compared to the wild-type
HIV-1, especially mutation in the first and second AP-1 sites
which caused a decrease of luciferase expression of 50.7% and
53.3%, respectively.
Altogether, these results show that mutations in the 5103
fragment AP-1 sites affect HIV-1 expression. These deleterious
effects observed with mutant viral stocks are likely to be a direct
consequence of impaired AP-1 binding to the mutated 5103
fragment since wild-type and mutant HIV-1 particles from the
viral stocks used in the infection studies are structurally similar at
both the RNA and protein levels.
Mutations in the intragenic AP-1 sites alter HIV-1
replication in T-lymphoid and promonocytic cell lines
In order to address the importance of the 5103 fragment AP-1
binding sites for HIV-1 replication in the two major cell targets of
HIV-1, i.e. T cells and macrophages, we infected T-lymphoid
Jurkat and promonocytic U937 cells with the wild-type and
mutant viral stocks. We subsequently monitored the growth
kinetics of the infection by measuring p24 production in the cell
supernatants over a period of 17 days and by quantifying viral
mRNA production at days 5, 10 and 15 post-infection. Figures 9A
and 9B show a representative replication curve of three
independent replication assays (each performed in triplicate) for
Jurkat and U937 cells, respectively.
Infection of T-lymphoid Jurkat cells with the wild-type virus
resulted in a strong viral production (Fig. 9A), whereas mutant
viruses revealed differences in replication rate and/or virus
production levels compared to the wild-type virus. At day 20
and later on, a rapid decrease in p24 production was observed,
reflecting the heavy reduction of viable cell counts (data not
shown). Mutant viruses HIV-1-AP-1#3mut, HIV-1-AP-1#1mut,
HIV-1-AP-1#1+2mut and HIV-1-AP-1#totmut exhibited repli-
cation kinetics analogous to that observed with the wild-type
control virus HIV-1, but with lower levels of viral production
(corresponding to a 46%, 49%, 53% and 53% decrease,
respectively, of p24 release from infected cultures on day 17
compared to the p24 release observed with the wild-type HIV-1)
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Figure 7. The AP-1 transcription factors c-Fos, JunB and JunD are recruited in vivo to the 5103 fragment region. HeLa cells were
transiently transfected with the wild-type pHIV-1 or the mutated pHIV-1-AP-1#totmut construct. Twenty-four hours post-transfection, cells were
mock-treated (-) or treated with PMA (+). Twenty-four hours post-induction, cells were cross-linked for 10 min at room temperature with 1%
formaldehyde. To detect chromosomal flanking regions, pellets were sonicated to obtain DNA fragments of an average size of 400 bp. Chromatin
immunoprecipitations were performed with specific antibodies directed against c-Fos, JunB, Fra-1 or JunD. To test aspecific binding to the beads, a
purified IgG was used as a control for immunoprecipitation. Quantitative PCR reactions were performed with oligonucleotide primers hybridizing
either in the nuc-1 region (termed nuc-1), or in a region overlapping the three AP-1 binding sites of the 5103 fragment (termed 5103 fragment), or in
the vpr gene (termed vpr gene) where no AP-1 binding sites have been previously reported. Fold enrichments were calculated as percentages of
immunoprecipitated DNA following the formula ‘‘Immunoprecipitated DNA (IP)*100/Input DNA (INP)’’. Values represent the means of triplicate
samples and standard errors of the means are indicated. An experiment representative of three independent ChIP assays is shown. (B) Mutations in
the intragenic AP-1 sites affect the PMA-inducible in vivo recruitment of RNA polymerase II to the HIV-1 59LTR region. Chromatin
immunoprecipitations were performed with a specific antibody directed against RNAPII and a purified IgG as a control. Quantitative PCR reactions
were performed with the same oligonucleotide primers and fold enrichments were calculated as in panel (A). Means and standard errors of the
means from one experiment representative of three independent ChIP assays are shown.
doi:10.1371/journal.pone.0019084.g007
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(Fig. 9A), thereby indicating a deleterious effect of the introduced
mutations for HIV-1 viral production. Moreover, infection of
Jurkat cells with the HIV-1-AP-1#2mut virus led to a very low
p24 release (reaching 88% decrease on day 17 compared to the
wild-type virus), reflecting severely reduced replication properties
(Fig. 9A). As shown in Figure 9B, all viruses produced lower
concentrations of viral p24 in promonocytic U937 cells and
mutant viruses affected HIV-1 replication in a similar manner
than what was observed in T-lymphoid Jurkat cells, except for
mutant HIV-1-AP-1#3mut. Of note, the HIV-1-AP-1#2mut
virus exhibited severely reduced replication properties, reaching
83% decrease of the p24 production at day 17. A second round of
Figure 8. Viral particles from mutant and wild-type virus stocks are similar at the protein and at the RNA levels. (A) Equivalent
amounts of viral particles (as assessed by p24 ELISA assays) from the wild-type and each AP-1 mutant virus stocks were pelleted by centrifugation,
lysed in Laemmli buffer and analyzed by Western blotting with an anti-HIV-1 immunoglobulin. The bands corresponding to the HIV-1 glycoprotein
gp160, reverse transcriptase p66/p51, integrase p32 and capsid p24 proteins are indicated. MW, molecular weight (indicated in kDa). (B) Viral RNAs
from equal amounts of viral particles were digested with DNase I and subsequently reverse-transcribed with random primers. First-strand viral cDNAs
were then quantified by qPCR with primers hybridyzing in the TAR region (as described in the Materials and Methods section). An arbitrary value of 1
was assigned to the result obtained with the wild type virus stock HIV-1. Means and standard errors of the means from two independent experiments
each performed in triplicate are indicated. (C) Mutations in the intragenic AP-1 binding sites affect HIV-1 expression. TZM-bl cells (66103
cells) were infected or not with equal amounts of wild-type HIV-1 or mutant virus stocks. At 72 h post-infection, TZM-bl cells were lysed and luciferase
activity was measured in cell lysates. Results are presented as histograms indicating the LuciferaseFirefly activity of the TZM-bl cells following infection
with wild-type versus mutant viruses. An arbitrary value of 100% was attributed to the result obtained with the wild-type HIV-1. Means and standard
errors of the means from one representative from three independent experiments each performed in triplicate are indicated. * indicates p,0.05
compared to the wild-type virus HIV-1.
doi:10.1371/journal.pone.0019084.g008
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infection of target Jurkat and U937 cells with supernatants
collected 18 days after the first infection allowed us to conclude
that all mutant viruses were competent in terms of infectivity in
both cell lines (data not shown).
In parallel, we quantified initiated (TAR) and elongated (Tat)
viral mRNAs produced in Jurkat and U937 infected cells at days 5,
10 and 15 post-infection (see Figures 9C and 9D, respectively). We
observed similar patterns of viral production with mutant versus
wild-type viral stocks than those observed by measuring p24
production in cell supernatants. Indeed, mutant HIV-1-AP-
1#2mut exhibited a highly affected replication profile in both
cell lines (reaching a 87% and 82% decrease of elongated
transcripts in Jurkat and U937 cells at day 15 post-infection,
respectively; Figures 9C and 9D). Mutant viruses HIV-1-AP-
1#3mut, HIV-1-AP-1#1mut, HIV-1-AP-1#1+2mut and HIV-1-
AP-1#totmut exhibited a similar behaviour than previously
measured in p24 assays since we observed a 48%, 52%, 39%
and 40% (17%, 54%, 37% and 52%) decrease of elongated
transcripts in Jurkat (U937) cells at day 15 post-infection.
The HIV-1-AP-1#totmut and the HIV-1-AP-1#1+2mut
viruses were less affected than the virus containing the individual
AP-1#2 site mutation, suggesting partial compensatory mecha-
nisms turned on by the virus when two or three intragenic AP-1
sites are mutated simultaneously to ensure its replication. These
mechanisms could, for example, involve the recruitment of other
transcription factors or co-factors in the intragenic region.
Noteworthy, we verified that mutations introduced in the
intragenic AP-1 sites did not significantly modify the splicing
pattern of viral transcripts by quantifying unspliced full-length
(9 kb), singly-spliced (4 kb) and multiply-spliced (2 kb) transcripts
for each mutant virus after infection (see Figure 10). We also
demonstrated that the reduced replication phenotypes observed
with the AP-1 mutant viruses were not due to a defect neither in
the protein nor in the RNA content of viral particles (Figures 8A
and 8B, respectively). Moreover, our ChIP results showed that the
role of intragenic AP-1 sites in HIV-1 replication takes place, at
least partly, at the transcriptional level since the increased RNAPII
in vivo recruitment to the viral promoter following PMA treatment
of the cells was affected by mutations in the intragenic AP-1
binding sites (Figure 7B).
Taken together, our results demonstrate that the integrity of the
5103 fragment AP-1 binding sites located 4 kb downstream of the
HIV-1 transcription start site is important, notably at the
transcriptional level, for an efficient HIV-1 replication in human
Figure 9. The AP-1 binding sites located in the 5103 fragment are important for viral replication. Jurkat (A and C) or U937 (B and D) cells
were infected with equivalent amounts of p24 concentration of wild-type (HIV-1), totally mutated (HIV-1-AP-1totmut), partially mutated (HIV-1-AP-
1#1+2mut) or individually mutated (HIV-1-AP-1#1mut, HIV-1-AP-1#2mut and HIV-1-AP-1#3mut) viral infectious stocks as described in the Materials
and Methods section. (A and B) Viral production in cell supernatants was quantified by measuring p24 antigen concentration in the culture
supernatants at different times following infection. The experiment shown is representative of at least 3 independent infection experiments (each
performed in triplicate). The means are presented and the variation for a given mutant between different experiments was,15% in each case. (C and
D) Total RNA was extracted from infected cells at days 5, 10 and 15 post-infection, digested with DNase I and reverse-transcribed using random
primers. First-strand cDNAs were analyzed by qPCR with the comparative Ct (DDCt) quantification method using the two following sets of primers:
initiated transcripts (TAR primers) and elongated transcripts (Tat primers) were quantified using b-actin to normalize the results. Means and standard
errors of the means from two independent experiments each performed in triplicate are indicated. * and ** indicate p,0.05 and p,0.1 compared to
the wild-type virus HIV-1 at day 15 post-infection.
doi:10.1371/journal.pone.0019084.g009
Intragenic AP-1 Sites Role in HIV-1 Replication
PLoS ONE | www.plosone.org 15 April 2011 | Volume 6 | Issue 4 | e19084
CD4+ T-lymphocytes and promonocytic cell lines, indicating a
positive regulatory function of the intragenic AP-1 sites.
Single-round HIV-1 infections of MDMs are affected by
mutations in the pol gene AP-1 binding sites
AP-1 transcription factors are known to play an important role
in myeloid cells [41]. Moreover, the DNaseI-hypersensitive site
HS7, which is part of the intragenic region, has been identified in a
cell line of monocytic origin (U1), whereas it was absent in two cell
lines of lymphoid origin (ACH2 and 8E5) [3,5]. Therefore, we
further evaluated the importance of the three AP-1 binding sites of
fragment 5103 on HIV-1 replication in primary monocyte-derived
macrophages (MDMs). Since HIV-1NL4.3 strain is not able to
infect human MDMs [42], we used wild-type and mutant HIV-1
viruses pseudotyped with the VSV-G glycoprotein to assess the
impact of the AP-1 mutations on viral expression in single-round
infections. p24 production in infected cell supernatants was used as
a marker of viral expression. Results of experiments performed
with MDMs from 3 different donors are presented as percentages
of p24 levels at day 10 for each mutant virus compared to the wild-
type virus (Figure 11).
p24 production resulting from MDMs transduction by the
mutants HIV-1-AP-1#1mutVSV, HIV-1-AP-3#totmutVSV, HIV-
1-AP-1#1+2mutVSV and HIV-1-AP-1#totmutVSV viruses was
reduced compared to that observed with the wild-type HIV-1VSV
(leading to a 40.1%, 31.7%, 37.6% and 52.2% decrease,
respectively). Importantly, mutation in the AP-1#2 site strongly
impaired MDMs transduction (80.3% decrease in p24 production
compared to the wild-type). Interestingly, mutation in the second
AP-1 site was the most deleterious in both cell lines and primary
macrophages, indicating an important role of the AP-1#-2 site for
HIV-1 replication. PCR quantification of late reverse transcriptase
products did not show substantial reductions in MDMs infected
with AP-1 mutated viruses compared to MDMs infected with the
wild-type HIV-1 virus, which could have explained the reduction
in p24 production we observed in our infection studies with
mutated viruses compared to wild-type virus (data not shown).
Therefore, these results suggest that the defect in viral expression
in MDMs transduced by the AP-1 mutated viruses is not caused by
pre-integration blocks.
Altogether, these results demonstrate the importance of the
intragenic AP-1 binding sites for efficient HIV-1 replication in
macrophages as a decrease in viral expression of AP-1 site mutant
viruses, and especially of the AP-1#2 site mutant virus, was
detected in transduction of primary MDMs with VSV-G
pseudotyped viruses (during single-round infections).
Discussion
Our laboratory has previously identified an important intra-
genic region in the HIV-1 genome, whose complete functional
unit is composed of the 5103 fragment, the hypersensitive site HS7
and the 5105 fragment [2,3,5,6] (Figure 1). These two fragments
(5103 and 5105) both exhibit a PMA-inducible enhancer activity
on the HSV TK promoter in HeLa cells, but no significant activity
in T-lymphoid and monocyte-macrophage cell lines [2]. AP-1
transcription factors are typically absent in quiescent cells but
significantly induced upon cellular activation, notably following
phorbol ester treatment of the cells [43]. In this regard, the three
AP-1 binding sites of fragment 5103 [7] were good candidates to
investigate the PMA-dependent enhancer activity of this fragment.
In the present report, we characterized biochemically and
functionally these three intragenic AP-1 binding sites by showing
the PMA-inducible in vitro binding and in vivo recruitment of the
AP-1 family members c-Fos, JunB and JunD to the 5103 fragment.
Our ex vivo transient transfection assays in the heterologous context
of the HSV TK promoter demonstrated that the intragenic AP-1
sites are fully responsible for the PMA-dependent enhancer
activity of fragment 5103. We further demonstrated that this
activity was completely inhibited by the overexpression of a
Figure 10. The splicing pattern of HIV-1 transcripts is unaffected by the mutations introduced in the intragenic AP-1 binding sites.
Total RNA was extracted from infected Jurkat or U937 cells (with wild-type or mutant virus stocks) at 5 days post-infection. After DNase I treatment,
total RNA was reverse-transcribed with random primers and first strand cDNAs were quantified with primers designed to quantify full-length
unspliced viral mRNAs, singly-spliced viral mRNAs and multiply-spliced viral mRNAs. The total amount of viral mRNAs for each virus was arbitrarily
attributed a value of 100% and the proportion of each type of transcript is presented as histograms indicating the means and standard errors of the
means from two independent experiments performed in duplicate.
doi:10.1371/journal.pone.0019084.g010
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dominant-negative A-Fos mutant. Moreover, we investigated the
biological significance of the intragenic AP-1 sites for HIV-1
replication. We produced wild-type and mutant viral stocks and
demonstrated the importance of the 5103 fragment AP-1 sites for
viral expression in HeLa-derived TZM-bl cells. Importantly,
infection of T-lymphoid Jurkat and promonocytic U937 cell lines
with wild-type and mutant viruses showed that mutation of the
intragenic AP-1 sites individually or in combination altered HIV-1
replication. Our ChIP results demonstrated that the deleterious
effect observed on HIV-1 replication with mutant viruses occurs
(at least partly) at the transcriptional level since we measured a ,
two fold decrease of the PMA-mediated RNAPII in vivo
recruitment to the viral promoter when the three intragenic AP-
1 sites were mutated simultaneously. Remarkably, mutations in the
pol gene AP-1 sites also affected viral replication in MDMs in
single-round infection experiments, in agreement with the
important role played by AP-1 in myeloid cells. Interestingly, at
day 15 post-infection with the AP-1 mutant viruses, we observed
the emergence of a low percentage (5 to 10%) of viruses that
reverted to the wild-type sequence or that harboured additional
mutations around the AP-1 sites possibly to counteract the
negative effects of the intragenic AP-1 sites mutations on viral
replication.
In this study, we observed some divergences between ex vivo
transient transfection assays and in vivo infection experiments
regarding the effects of certain AP-1 mutants. Several phenomena
may explain these differences. They may result from the fact that
our studies were performed in the heterologous context of the
HSV TK promoter (for transfection assays) and in the homologous
context of the entire HIV-1NL4.3 isolate (for infection experiments).
Indeed, viral replication involves other transcription factors that
bind elsewhere in the HIV-1 provirus, cis-regulating elements
adjacent to fragment 5103 and the chromatin organization of the
integrated provirus, notably of the intragenic region. In this
regard, transient transfection experiments may not reflect the
regulation found in vivo since transiently transfected DNA is not
assembled into physiological chromatin. In addition, the pool of
cellular transcription factors differs from one cell type to another,
the differences in the availability of AP-1 (or of certain members of
the AP-1 family) or of another co-factor important for AP-1
activity in those particular cell lines may have consequences on the
observed effect of the intragenic AP-1 binding sites mutations for
HIV-1 replication and/or for the 5103 fragment enhancer activity.
Similar divergences between transient transfection studies and in
vivo functional studies have been previously reported for HIV-1 by
different groups including our laboratory [5,6,9,44,45,46]. More-
over, it may seem surprising that the HIV-1 AP-1#2 mutant virus
was more deleterious for HIV-1 replication than the HIV-
1#1+2mut and the HIV-1#totmut viruses, which also contain
the AP-1#2 site mutation. However, since HIV-1 suffers from a
high error rate during the reverse transcription step, it has
developed rescue mechanisms. Here, the virus may activate such
rescue mechanisms when two or three AP-1 sites are defective, by
recruiting other transcription factors or co-factors for instance,
while mutation of a unique intragenic AP-1 site may not be
sufficient to turn on these rescue mechanisms.
AP-1 transcription factors are known to play important roles in
myeloid development [41], whereas they are slightly expressed in
Jurkat cells [47]. The binding and functional studies reported here
were performed in epithelial HeLa cells, which contain a high
endogenous level of AP-1 transcription factors [47], because we
could not observe PMA-mediated activation of AP-1 in the two
other cell lines used (Jurkat and U937) despite many attempts (data
not shown). Indeed, it has been reported that transformed cells
often have demonstrable defects in cell signalling. For instance,
Ras-mediated extracellular regulated kinase (ERK) activation
varies between primary T cells and Jurkat T cells [48,49].
Wabnitz and colleagues have reported that, whereas it is not the
case in Jurkat lymphoma cells, in peripheral blood T lymphocytes,
phorbol esters activate Ras and the phosphatidylinositol-3-kinase
(PI3K) substrate Akt [50].
Importantly, our single-round infections of MDMs strongly
supported the importance of the intragenic AP-1 sites for an
efficient HIV-1 replication in macrophages since their mutation
affected viral expression in transduced cells. Interestingly, the
hypersensitive site HS7 has been identified in the latently-infected
monocytic (U1) cell line, but not in the T-lymphoid (ACH2 and
8E5) cell lines [3], supporting a cell-type specific role of the
intragenic region. Such cell-type-specific properties could result
from the presence of several binding sites for other transcription
factors, such as binding sites for the macrophage and B-cell specific
transcription factor PU.1 that we identified in the intragenic
region ([6] and unpublished data from our laboratory). Indeed,
previous studies have reported that AP-1 and PU.1 can cooperate
in the regulation of cellular genes in macrophages [48], such as for
the adipose differentiation-related protein gene [51]. Interestingly,
c-Jun homodimers can function as coactivators for PU.1 in
macrophages as demonstrated on the monocyte-specific macro-
phage colony-stimulating factor (M-CSF) receptor promoter [52].
Further investigations concerning the functional interplay between
the AP-1 and PU.1 binding sites in the intragenic region will be
Figure 11. Single-round HIV-1 infections of MDMs are affected
by mutations in the intragenic AP-1 binding sites. Monocyte-
derived macrophages from three healthy donors were isolated and
individually infected with VSV-G pseudotyped HIV-1NL4.3 viruses (HIV-
1VSV, HIV-1-AP-1#totmutVSV, HIV-1-AP-1#1mutVSV, HIV-1-AP-
1#2mutVSV, HIV-1-AP-1#3mutVSV, HIV-1-AP-1#1+2mutVSV). Production
of p24 in the culture supernatant was measured by ELISA at day 10
post-infection. Results are presented as histograms indicating the p24
production level of each mutant virus compared to the wild-type virus
HIV-1VSV, which was assigned an arbitrary value of 100%, and
correspond to results obtained from three independent donors in
order to take into account the variability that may exist between
donors. Means and standard errors of the means are indicated.
* indicates p,0.05 compared to the wild-type virus HIV-1VSV.
doi:10.1371/journal.pone.0019084.g011
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needed to unveil possible mechanisms involved in the cell-type-
specific role of the intragenic region in macrophages. Other viruses
have been shown to possess such intragenic regulatory regions
contributing to transcriptional regulation by adding a cellular
specificity, including the human hepatitis B virus and the closely
related woodchuck hepatitis virus [53,54].
Previous studies about the role played by AP-1 in HIV-1
transcription and expression were centred on the AP-1 binding
sites present in the 59LTR and leader region of HIV-1. TRE
elements have been previously characterized in the NRE region (at
positions nt 151-175 and nt 213-233) of different neuronal strains
[8] and downstream of the transcription start site in the HS4
region [the AP-1(I) site (nt 541 to 547), AP-1(II) site (nt 572 to 578)
and AP-1(III) site (nt 609 to 614)] [9]. Other viruses including
feline immunodeficiency virus [55], foamy viruses [56,57],
Kaposi’s sarcoma associated herpes virus [58,59], human
papillomavirus [60,61], visna virus [62] or human T-cell
leukemia/lymphoma virus type I (HTLV-I) [63,64] use AP-1
factors either to regulate their own replication or to interfere with
host cell gene regulation. In recent years, the interest for the role
played by chronic immune activation and inflammation in HIV-1
pathogenesis increasingly raised. Indeed, quite paradoxically,
chronic immune activation has been associated with high levels
of viremia and is a primary driver of HIV-1 progression to AIDS.
Of note, inducible transcription factors such as AP-1 or NF-kB are
involved in inflammation processes and activate transcription of
antiviral and inflammatory genes. They also increase HIV-1
expression level by binding to the viral 59LTR and leader region
and, concerning AP-1, in the intragenic cis-regulatory region. In
this context, AP-1 proteins, among other inducible cellular
transcription factors, might play a role both in the transactivation
of viral gene expression and in the inflammation process that
together lead to chronic immune activation in HIV-infected
patients.
In conclusion, the 5103 fragment, containing the three
intragenic AP-1 binding sites characterized in this report, in
cooperation with the adjacent HS7 region and the 5105 fragment
(Fig. 1) are the components of a large intragenic regulatory region
that could either bring an additional cellular specificity, and/or
increase the strength of the promoter/enhancer unit located in the
HIV-1 59LTR, and/or allow viral responses to a broader variety
of exogenous stimuli. The intragenic AP-1 binding sites corre-
spond to an additional factor in an already complex network of
regulators affecting HIV-1 replication at the transcriptional level,
thereby contributing to an efficient viral control of the infection.
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